Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

08/19/2011 | 08:40am US/Eastern
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

React to this article
Latest news on CYTOKINETICS, INC.
02/04 CYTOKINETICS : to Participate in Upcoming Investor Conferences
02/03 Cytokinetics to Participate in Upcoming Investor Conferences
02/02 CYTOKINETICS : to Announce Fourth Quarter Results on February 16, 2016
02/02 Cytokinetics to Announce Fourth Quarter Results on February 16, 2016
01/11 CYTOKINETICS : Other Events, Financial Statements and Exhibits (form 8-K)
01/11 Cytokinetics Outlines Vision 2020 Strategic Initiative to Advance Portfolio o..
01/11 CYTOKINETICS : Outlines Vision 2020 Strategic Initiative to Advance Portfolio of..
01/10 Cytokinetics Presents Analyses Demonstrating Predictive Value of Slow Vital C..
01/05 CYTOKINETICS : Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patien..
01/04 CYTOKINETICS : Other Events (form 8-K)
Advertisement
Income Statement Evolution
More Financials